Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
Still feeling the Vioxx pain Ten years after Vioxx was abruptly withdrawn from the market, its story is still affecting society’s perception of the drug regulatory system and the safety of non-steroidal anti-inflammatory drugs.…
Rheumatoid arthritis: a patient journeyThis case study aims to help you understand the diagnosis of rheumatoid arthritis, the different medicines that may be prescribed and the support you can give patients…
Rheumatoid arthritis: management Evidence in support of early and aggressive pharmacological intervention in rheumatoid arthritis continues to be gathered. DMARDs, corticosteroids and biologics are the main drugs in the armoury.…
Rheumatoid arthritis: features, causes and diagnosis Social and financial independence can be lost when a person develops severe rheumatoid arthritis. Prompt diagnosis and treatment can improve outcomes for patients and reduce costs to society.…
